在炎症条件下表面抗血栓聚合物涂层的战略和研究进展
Zehong Xiang1,2, Honghong Chen3, Feng Wu1,2
1Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, 518000, China.
Macromolecular bioscience
|April 2, 2025
概括
心血管疾病 (CVD) 构成了全球死亡风险. 本综述探讨了医疗器械的抗炎涂层,以对抗长期血栓形成,解决免疫排斥和炎症.
科学领域:
- 生物材料科学 生物材料科学
- 心血管医学 心血管医学
- 免疫学 免疫学 免疫学
背景情况:
- 心血管疾病 (CVD) 是全球主要的死亡原因.
- 接触血液的医疗器械往往需要抗凝剂涂层,以防止血栓形成.
- 目前的策略有效地减少了短期风险,但与长期植入的设备斗争.
研究的目的:
- 审查包含抗炎性质的抗血栓涂层策略.
- 为应对长期医疗器械中晚期血栓形成的挑战.
- 突出调节炎症的研究贡献,以改善抗血栓结局.
主要方法:
- 审查关于抗血栓涂层的现有文献.
- 专注于使用抗炎药物的策略.
- 分析导致晚期血栓形成的机制,包括免疫排斥和慢性炎症.
主要成果:
- 有证据表明,免疫排斥和慢性炎症是晚期血栓形成的关键驱动因素.
- 调节炎症对于实现长期抗血栓作用至关重要.
- 已经确定了几种代表性的抗炎抗血栓涂层策略.
结论:
- 抗炎方法是长期抗血栓涂层的一个有希望的策略.
- 解决炎症对于植入医疗器械的成功至关重要.
- 在这个领域进行进一步的研究可以改善心血管疾病患者的治疗结果.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
532
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
532
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
986
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
986


